The short answer
Cross-border clinic ads fail on compliance, not creative — build a claims matrix and assign a named reviewer before production.
Medical and aesthetic advertising is regulated differently in Japan and Korea, and cross-border patient acquisition fails most often on compliance rather than creative. Treat claim review as part of the launch plan, not an afterthought.
Japan's Pharmaceutical and Medical Device Act (薬機法) and related medical advertising guidelines restrict efficacy claims, testimonials, and certain before-and-after imagery. Korea's medical advertising review system requires prior screening for many clinic advertisements.
Build a claims matrix before writing creative: list each benefit you want to communicate, the evidence behind it, and whether it is permissible in the target market. Anything unsupported is removed before production, not during media review.
Before-and-after photography, patient testimonials, and superlatives ('best', 'safest', 'guaranteed') are the most common rejection triggers. Prepare compliant alternatives—process explanations, qualifications, and factual scope of service—in advance.
Assign one named reviewer accountable for regulated claims in each market. The reviewer signs off on copy, imagery, and landing pages together, because the ad and the destination must tell a consistent, compliant story.